{"id":"W4200183746","doi":"10.1016/j.dsx.2021.102382","title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial","year":2021,"lang":"en","type":"review","venue":"Diabetes & Metabolic Syndrome Clinical Research & Reviews","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Merck Sharp and Dohme; Novo Nordisk; University of Glasgow; British Heart Foundation; Sanofi; Kowa Company; Amgen; Boehringer Ingelheim; Novartis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Abbott Laboratories","keywords":"Glucagon-like peptide 1 receptor; Exenatide; Agonist; Medicine; Mace; Internal medicine; Receptor; Clinical trial; Type 2 diabetes; Diabetes mellitus; Dulaglutide; Pharmacology; Endocrinology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003653077,0.002156503,0.01079002,0.001138879,0.0002605986,0.001691769,0.001268415,0.001309147,0.002956168],"category_scores_gemma":[0.005056197,0.0009723614,0.01957181,0.00184589,0.0003207089,0.0009647084,0.0009540315,0.003046578,0.0003110224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006387633,"about_ca_system_score_gemma":0.0007227148,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00303043,"about_ca_topic_score_gemma":0.007098848,"domain_scores_codex":[0.9980513,0.0009876975,0.0003626394,0.0003007,0.0001759825,0.0001216963],"domain_scores_gemma":[0.9977646,0.001552899,0.000363549,0.0001187969,0.0001235188,0.00007668064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.02125891,0.00009875961,0.007801278,0.07752085,0.8511989,0.0001285899,0.00005470172,0.001001243,0.0004700095,0.0001813725,0.001989933,0.03829542],"study_design_scores_gemma":[0.006222747,0.000673483,0.01180034,0.004007869,0.9733055,0.00008960038,0.00005356404,0.0004263775,0.0001457348,0.0003991665,0.002824868,0.00005064841],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01675675,0.9811198,0.0005923965,0.0002352627,0.0003088477,0.0000634473,0.0005264049,0.0000383711,0.0003587455],"genre_scores_gemma":[0.3115005,0.6813476,0.002419915,0.001347952,0.0008523267,0.0002699267,0.001491128,0.00005687032,0.0007137322],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01079002,"threshold_uncertainty_score":0.01931953,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2385434492425108,"score_gpt":0.4451228867651156,"score_spread":0.2065794375226049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}